Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High?

Verve Therapeutics (VERV) closed the last trading session at $5.29, gaining 25.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of$ 24.75 indicates a 367.9% upside potential.The average comprises eight short-term price targets ranging from a low of $15 to a high of$ 39, with a standard deviation of $7.81. While the lowest estimate indicates an increase of 183.6% from the current pri ...